The Medication Shield, the pharmacovigilance support technology

The artificial intelligence solution for pharmacovigilance that facilitates the management of adverse event reports.

What is the Medication Shield?

The "Medication Shield" technology manages in real-time adverse drug reactions (ADRs) signals by encoding them automatically into a standardized, international terminology (MedDRA) and ranks them by severity. This helps pharmacovigilance teams daily in their management of ADRs reports.

What is the Medication Shield?
The Medication Shield identifies in real-time the drugs involved by coding them in ATC class.

Drug identification

The Medication Shield identifies in real-time the drugs involved by coding them in ATC class.

Using NLP algorithms, the Medication Shield detects adverse events by coding them in MedDRA terminology.

ADEs Detection

Using NLP algorithms, the Medication Shield detects adverse events by coding them in MedDRA terminology.

It analyzes the seriousness level of adverse events to enable their classification and increases pharmacovigilance teams’ reactivity.

Seriousness Level Analysis

It analyzes the seriousness level of adverse events to enable their classification and increases pharmacovigilance teams’ reactivity.

Finally, it determines the expected or unexpected nature of the ADE and its frequency of occurrence according to the drug monograph.

Advanced ADE Characteristic Identification

Finally, it determines the expected or unexpected nature of the ADE and its frequency of occurrence according to the drug monograph.

Real-time coding of ADEs according to the MedDRA classification

The Medication Shield's natural language processing (NLP) algorithms extract the terms used when reporting an adverse reaction and find its correspondence according to the MedDRA classification. The Medication Shield then analyzes whether this adverse reaction is expected, its level of severity and its frequency.

Request a demo

Automating pharmacovigilance with the Medication Shield

The Medication Shield unifies all the information on adverse drug events and facilitates decision-making by pharmacovigilants.

Improves Patient Safety

Improves Patient Safety

Real-time detection of pharmacovigilance signals

Real-time detection of pharmacovigilance signals

Precise vision of the benefit-risk balance

Precise vision of the benefit-risk balance

Harmonization of ADEs coding (MedDRA)

Harmonization of ADEs coding (MedDRA)

Deployable pharmacovigilance technology on a country level

Deployable pharmacovigilance technology on a country level

Time-saving for pharmacovigilance teams

Time-saving for pharmacovigilance teams

Seamless integration with third-party ADE management software

The Medication Shield integrates easily with third-party ADE management softwares. It allows pharmacovigilants to benefit from the power of the Medication Shield’s artificial intelligence while continuing to use their everyday softwares.

Contact us

The Medication Shield deployment for the COVID-19 vaccination campaign in France

The Medication Shield is also used in the COVID-19 vaccination campaign in France. The integration of the Medication Shield in partnership with the ANSM facilitates on a daily basis the management of adverse event reports by the pharmacovigilance teams.

The Medication Shield deployment for the COVID-19 vaccination campaign in France
The reporting portal implemented by the French Ministry of Health allows the Regional Pharmacovigilance Centers (CRPVs) to be notified of ADRs detected by healthcare professionals (HCP), patients, or by the pharmaceutical industry.

Reporting of potential adverse drug reactions (ADRs)

The reporting portal implemented by the French Ministry of Health allows the Regional Pharmacovigilance Centers (CRPVs) to be notified of ADRs detected by healthcare professionals (HCP), patients, or by the pharmaceutical industry.

Synapse Medicine uses its Medication Intelligence technology expertise to help Regional Pharmacovigilance Centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM) to manage ADR reports. The "Medication Shield" technology encodes ADR signals according to an international terminology (MedDRA) and ranks them by severity.

The Medication Shield scope of action

Synapse Medicine uses its Medication Intelligence technology expertise to help Regional Pharmacovigilance Centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM) to manage ADR reports. The "Medication Shield" technology encodes ADR signals according to an international terminology (MedDRA) and ranks them by severity.

Regional Pharmacovigilance Centers can thereby benefit from an easier and faster reading of data linked to ADR reports. Synapses' technology is a valuable time-saver that allows them to focus their attention on the most complex cases.

Analysis by pharmacovigilance teams

Regional Pharmacovigilance Centers can thereby benefit from an easier and faster reading of data linked to ADR reports. Synapses' technology is a valuable time-saver that allows them to focus their attention on the most complex cases.

The Medication Shield simplifies ADR signals processing and allows health authorities to detect them faster after the drug is commercialized.

French national health surveillance

The Medication Shield simplifies ADR signals processing and allows health authorities to detect them faster after the drug is commercialized.

The integration of the Medication Shield within the French pharmacovigilance system

Check our infographic that explains how the Medication Shield technology is integrated into the French pharmacovigilance system.

Our latest scientific publication on the Medication Shield

In Clinical Pharmacology & Therapeutics, a leading international scientific journal, find our latest publication on the "Medication Shield" technology: Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.

Synapse Medicine, the French FDA (ANSM), the Pharmacology Department of the Bordeaux University Hospital, and the Pharmacoepi - Inserm U1219 BPH team of the University of Bordeaux.

Frequently asked questions

What is an adverse drug reaction (ADR)?

What is an adverse drug reaction (ADR)?

What is pharmacovigilance? 

What is pharmacovigilance? 

How do you report ADRs in France?

How do you report ADRs in France?

Which role plays Synapse Medicine within the pharmacovigilance system?

Which role plays Synapse Medicine within the pharmacovigilance system?

Why did the CRPVs integrate the Medication Shield?

Why did the CRPVs integrate the Medication Shield?

Why did the ANSM choose to work with Synapse Medicine?

Why did the ANSM choose to work with Synapse Medicine?

What are the terms of the contracts between Synapse Medicine and the ANSM?

What are the terms of the contracts between Synapse Medicine and the ANSM?

Is Synapse Medicine independent from the pharmaceutical industry? 

Is Synapse Medicine independent from the pharmaceutical industry? 

What is the ANSM?

What is the ANSM?

What is a CRPV?

What is a CRPV?

Synapse Medicines' collaboration with public institutions

Since its inception in 2017 by HCPs, Synapse Medicine has collaborated with some of the most significant french Hospitals and public health institutions.

The COVERAGE clinical trial

The COVERAGE clinical trial

Synapse Medicine made an unprecedented technology platform available to the COVERAGE clinical trial led by the Bordeaux University Hospital, one of the most significant clinical trials on primary care conducted during COVID-19 context.

To support mobile teams in their randomized chosen treatment administration, the platform helps physicians to check instantly whether this treatment is suitable or not with the patients' regular drug use.

A valuable time saver for HCPs, which is also increasing patients' safety.

Why was the Medication Shield created?

When a drug is commercialized, it is always monitored by a pharmacovigilance system to evaluate its risks. This system involves healthcare professionals, CRPVs, and the ANSM. These monitoring activities include collecting a significant amount of data that have to be analyzed and sorted to take corrective measures if needed.

The Medication Shield technology was developed to make the management of ADR reports easier for pharmacovigilant experts.

This was made possible thanks to the collaboration of the CRPVs pharmaceutical expertise, the ANSM, and Synapse Medicines' technology, which is beneficial to the populations' safety.

Dr. Louis Letinier - Medical Director and Co-Founder Synapse Medicine

Létinier, L. et al. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.Clin. Pharmacol. Ther. 110, 392–400 (2021).

Do you have any questions related to the Medication Shield?

You can ask us any questions related to the Medication Shield technology via this form. Our team will make sure to answer your request as soon as possible.